AR003473A1 - Uso de la l-carnitina o una acil l-carnitina en donde el acilo es seleccionado del grupo que comprende acetilo, propionilo, butirilo, valerilo e isovalerilo, o de una sal farmacologicamente aceptable de las mismas para la produccion de un medicamento - Google Patents
Uso de la l-carnitina o una acil l-carnitina en donde el acilo es seleccionado del grupo que comprende acetilo, propionilo, butirilo, valerilo e isovalerilo, o de una sal farmacologicamente aceptable de las mismas para la produccion de un medicamentoInfo
- Publication number
- AR003473A1 AR003473A1 ARP960103845A AR10384596A AR003473A1 AR 003473 A1 AR003473 A1 AR 003473A1 AR P960103845 A ARP960103845 A AR P960103845A AR 10384596 A AR10384596 A AR 10384596A AR 003473 A1 AR003473 A1 AR 003473A1
- Authority
- AR
- Argentina
- Prior art keywords
- acil
- carnitine
- pharmacologically acceptable
- isovaleril
- butyrile
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 title 2
- -1 PROPIONYL Chemical class 0.000 title 1
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 abstract 1
- 206010037660 Pyrexia Diseases 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 229940106189 ceramide Drugs 0.000 abstract 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 abstract 1
- 230000015271 coagulation Effects 0.000 abstract 1
- 238000005345 coagulation Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 abstract 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se revela el uso terapéutico de aminoácidos básicos, aminoácidos básicos acilados y sus sales farmacológicamente aceptables para la preparación de unmedicamento para la profilaxis de enfermedades o el tratamiento terapéutico de trastornoscelu lares acompanados por altos niveles de ceramida, tales comolas inflamaciones intestinales, la coagulación intravascular difusa, fiebre, catabolismo de proteínas, endomiocarditis, trombosis capilar, etc.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT95RM000545A IT1277898B1 (it) | 1995-08-03 | 1995-08-03 | Uso di amminoacidi basici, di acil derivati di amminoacidi basici e di loro sali farmaceuticamente accettabili per la profilassi di malattie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR003473A1 true AR003473A1 (es) | 1998-08-05 |
Family
ID=11403513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP960103845A AR003473A1 (es) | 1995-08-03 | 1996-08-02 | Uso de la l-carnitina o una acil l-carnitina en donde el acilo es seleccionado del grupo que comprende acetilo, propionilo, butirilo, valerilo e isovalerilo, o de una sal farmacologicamente aceptable de las mismas para la produccion de un medicamento |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US6114385A (es) |
| EP (1) | EP0844875B1 (es) |
| JP (1) | JPH11510182A (es) |
| KR (1) | KR100423760B1 (es) |
| CN (1) | CN1138539C (es) |
| AR (1) | AR003473A1 (es) |
| AT (1) | ATE349206T1 (es) |
| AU (1) | AU713207B2 (es) |
| BR (1) | BR9610106A (es) |
| CA (1) | CA2228281C (es) |
| DE (1) | DE69636792T2 (es) |
| DK (1) | DK0844875T3 (es) |
| ES (1) | ES2279523T3 (es) |
| IT (1) | IT1277898B1 (es) |
| PT (1) | PT844875E (es) |
| RU (1) | RU2179850C2 (es) |
| TW (1) | TW434011B (es) |
| WO (1) | WO1997005862A2 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1277898B1 (it) | 1995-08-03 | 1997-11-12 | Mendes Srl | Uso di amminoacidi basici, di acil derivati di amminoacidi basici e di loro sali farmaceuticamente accettabili per la profilassi di malattie |
| IT1277897B1 (it) * | 1995-08-03 | 1997-11-12 | Mendes Srl | Uso della l-carnitina,di suoi derivati e di loro sali farmaceuticamen- te accettabili in combinazione con farmaci antiretrovirali per ridurre |
| IT1284661B1 (it) * | 1996-06-06 | 1998-05-21 | Sigma Tau Ind Farmaceuti | Uso di alcanoil l-carnitine nel trattamento terapeutico di malattie infiammatorie croniche intestinali. |
| FR2778562B1 (fr) * | 1998-05-14 | 2000-08-04 | Sephra | Composition pharmaceutique, hygienique et/ou cosmetique contenant de l'eau de mer et de l'arginine |
| ES2235499T3 (es) * | 1998-07-30 | 2005-07-01 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Uso de derivados de propionil l-carnitina y de acetil l-carnitina en la preparacion de medicamentos con actividad anticancerigena. |
| IT1302289B1 (it) | 1998-09-30 | 2000-09-05 | Univ Catania | Composizioni farmaceutiche ad attivita' antineoplastica |
| CA2367002A1 (en) * | 1999-03-19 | 2000-09-28 | Michael A. Moskowitz | Increasing cerebral bioavailability of drugs |
| US20010025027A1 (en) * | 2000-03-07 | 2001-09-27 | Sonis Stephen T. | Inhibition of ceramide for the prevention and treatment of oral mucositis induced by antineoplastic drugs or radiation |
| WO2002060431A1 (en) * | 2001-01-30 | 2002-08-08 | Ajinomoto Co., Inc. | Remedies/preventives for inflammatory diseases |
| US20080145424A1 (en) * | 2002-10-24 | 2008-06-19 | Enos Phramaceuticals, Inc. | Sustained release L-arginine formulations and methods of manufacture and use |
| EP1562555A2 (en) * | 2002-10-24 | 2005-08-17 | Enos Pharmaceuticals, Inc. | Sustained release l-arginine formulations and methods of manufacture and use |
| IL156670A0 (en) * | 2003-06-26 | 2004-01-04 | Zvi Zolotariov | Aloe suppositories |
| JP2007521324A (ja) * | 2003-09-29 | 2007-08-02 | エノス ファーマシューティカルズ, インク. | 徐放性l−アルギニン調合物並びにその製造法及び使用法 |
| JP2007055900A (ja) * | 2003-12-15 | 2007-03-08 | Ajinomoto Co Inc | 炎症性疾患の治療及び予防用医薬組成物 |
| US20050232911A1 (en) * | 2004-04-19 | 2005-10-20 | Schreiber Brian D | Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid |
| RU2268718C1 (ru) * | 2004-11-09 | 2006-01-27 | Казанский государственный медицинский университет | Способ предотвращения развития осложнений экспериментального инфаркта миокарда у крыс |
| EA019268B1 (ru) * | 2010-12-01 | 2014-02-28 | Общество С Ограниченной Ответственностью "Анвилаб" | Комбинированное средство, обладающее гепатопротекторным действием |
| CN103142735B (zh) * | 2013-03-09 | 2014-07-23 | 河北工程大学 | 一种治疗鸭病毒性肝炎的中药口服液 |
| EP3764103A1 (en) * | 2019-07-12 | 2021-01-13 | Urgo Recherche Innovation Et Developpement | Method of diagnosis or prognosis of a non-healing or chronic wound |
| US20230346735A1 (en) * | 2020-04-28 | 2023-11-02 | Lonza Greenwood Llc | Nutritional Composition Comprising Carnitine and Method for Treating or Preventing an Infection in a Mammal |
| US20250360158A1 (en) * | 2022-06-13 | 2025-11-27 | Neubase Therapeutics, Inc. | Oligonucleotide analogue formulations |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU518617B2 (en) * | 1977-04-29 | 1981-10-08 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Therapeutic application of acetyl-d, 1-carnitine |
| DE2946563C2 (de) * | 1979-11-17 | 1987-04-30 | B. Braun Melsungen Ag, 3508 Melsungen | Aminosäurelösung zur parenteralen Infusion |
| JPH0247447B2 (ja) * | 1982-05-27 | 1990-10-19 | Teijin Ltd | Kohotaikanohikuiigmsoseibutsu |
| JPS6130567A (ja) * | 1984-07-23 | 1986-02-12 | Shiseido Co Ltd | 尿素の安定化法 |
| JPH02124822A (ja) * | 1988-11-02 | 1990-05-14 | Eisai Co Ltd | セファロスポリン含有注射用組成物 |
| IT1224842B (it) * | 1988-12-27 | 1990-10-24 | Sigma Tau Ind Farmaceuti | Uso di derivati della l-carnitina nel trattamento terapeutico delle alterazioni degenerative del sistema nervoso |
| US6294520B1 (en) * | 1989-03-27 | 2001-09-25 | Albert T. Naito | Material for passage through the blood-brain barrier |
| EP0400547A1 (en) * | 1989-06-02 | 1990-12-05 | Abbott Laboratories | Parenteral nutrition product |
| IT1244636B (it) * | 1991-01-04 | 1994-08-08 | Sigma Tau Ind Farmaceuti | Uso dell'acetil l-carnitina nel trattamento terapeutico del coma e composizioni farmaceutiche utili in tale trattamento. |
| IT1248321B (it) * | 1991-05-15 | 1995-01-05 | Sigma Tau Ind Farmaceuti | Uso di esteri di acil l-carnitine con l'acido gamma-idrossibutirrico per produrre composizioni farmaceutiche per il trattamento di epatopatie |
| IT1245869B (it) * | 1991-06-05 | 1994-10-25 | Sigma Tau Ind Farmaceuti | Impiego di propionil l-carnitina per il recupero del tono muscolare in soggetti immobilizzati |
| IT1254136B (it) * | 1992-01-16 | 1995-09-08 | Sigma Tau Ind Farmaceuti | Esteri di acil carnitine con alcooli alifatici a lunga catena e composizioni farmaceutiche che li contengono, ad attivita' antimicotica. |
| AU6922994A (en) * | 1993-06-21 | 1995-01-17 | Bernardini, Attilio | Use of acylcarnitin to treat illnesses caused by aids |
| IT1277898B1 (it) | 1995-08-03 | 1997-11-12 | Mendes Srl | Uso di amminoacidi basici, di acil derivati di amminoacidi basici e di loro sali farmaceuticamente accettabili per la profilassi di malattie |
| IT1277897B1 (it) | 1995-08-03 | 1997-11-12 | Mendes Srl | Uso della l-carnitina,di suoi derivati e di loro sali farmaceuticamen- te accettabili in combinazione con farmaci antiretrovirali per ridurre |
| IT1283951B1 (it) | 1996-03-15 | 1998-05-07 | Mendes Srl | Uso della acetil l-carnitina o dei suoi sali farmacologicamente accettabili per il trattamento terapeutico o la profilassi di |
-
1995
- 1995-08-03 IT IT95RM000545A patent/IT1277898B1/it active IP Right Grant
-
1996
- 1996-07-19 CA CA002228281A patent/CA2228281C/en not_active Expired - Fee Related
- 1996-07-19 KR KR10-1998-0700816A patent/KR100423760B1/ko not_active Expired - Fee Related
- 1996-07-19 RU RU98103503/14A patent/RU2179850C2/ru not_active IP Right Cessation
- 1996-07-19 AT AT96924125T patent/ATE349206T1/de not_active IP Right Cessation
- 1996-07-19 DE DE69636792T patent/DE69636792T2/de not_active Expired - Lifetime
- 1996-07-19 JP JP9508283A patent/JPH11510182A/ja not_active Ceased
- 1996-07-19 ES ES96924125T patent/ES2279523T3/es not_active Expired - Lifetime
- 1996-07-19 AU AU64691/96A patent/AU713207B2/en not_active Ceased
- 1996-07-19 EP EP96924125A patent/EP0844875B1/en not_active Expired - Lifetime
- 1996-07-19 WO PCT/IT1996/000147 patent/WO1997005862A2/en not_active Ceased
- 1996-07-19 BR BR9610106A patent/BR9610106A/pt not_active Application Discontinuation
- 1996-07-19 PT PT96924125T patent/PT844875E/pt unknown
- 1996-07-19 CN CNB961965282A patent/CN1138539C/zh not_active Expired - Fee Related
- 1996-07-19 DK DK96924125T patent/DK0844875T3/da active
- 1996-07-19 US US09/000,203 patent/US6114385A/en not_active Expired - Fee Related
- 1996-07-20 TW TW085108859A patent/TW434011B/zh not_active IP Right Cessation
- 1996-08-02 AR ARP960103845A patent/AR003473A1/es not_active Application Discontinuation
-
2000
- 2000-04-27 US US09/558,860 patent/US6350782B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1138539C (zh) | 2004-02-18 |
| US6114385A (en) | 2000-09-05 |
| WO1997005862A2 (en) | 1997-02-20 |
| JPH11510182A (ja) | 1999-09-07 |
| EP0844875A2 (en) | 1998-06-03 |
| BR9610106A (pt) | 1999-02-23 |
| DK0844875T3 (da) | 2007-04-10 |
| IT1277898B1 (it) | 1997-11-12 |
| CA2228281A1 (en) | 1997-02-20 |
| CN1193911A (zh) | 1998-09-23 |
| WO1997005862A3 (en) | 1997-04-17 |
| US6350782B1 (en) | 2002-02-26 |
| EP0844875B1 (en) | 2006-12-27 |
| ITRM950545A1 (it) | 1997-02-03 |
| DE69636792D1 (de) | 2007-02-08 |
| MX9800916A (es) | 1998-10-31 |
| KR100423760B1 (ko) | 2004-08-25 |
| DE69636792T2 (de) | 2007-10-04 |
| ES2279523T3 (es) | 2007-08-16 |
| ATE349206T1 (de) | 2007-01-15 |
| HK1015274A1 (en) | 1999-10-15 |
| TW434011B (en) | 2001-05-16 |
| RU2179850C2 (ru) | 2002-02-27 |
| AU6469196A (en) | 1997-03-05 |
| KR19990036148A (ko) | 1999-05-25 |
| CA2228281C (en) | 2008-03-25 |
| AU713207B2 (en) | 1999-11-25 |
| ITRM950545A0 (it) | 1995-08-03 |
| PT844875E (pt) | 2007-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR003473A1 (es) | Uso de la l-carnitina o una acil l-carnitina en donde el acilo es seleccionado del grupo que comprende acetilo, propionilo, butirilo, valerilo e isovalerilo, o de una sal farmacologicamente aceptable de las mismas para la produccion de un medicamento | |
| BR9611015A (pt) | Composto, composição farmacêutica e processo para o tratamento de uma doença inflamatória suscetìvel ao tratamento com um agente não-tóxico anti-inflamatório não-esteróide, sal farmaceuticamente aceitável, utilização de um composto | |
| FI20105844L (fi) | Farmaseuttisia koostumuksia IL-6:n tuoton aiheuttamien sairauksien hoitoon | |
| BR0009042A (pt) | Composto, uso do mesmo, processo para prepararum composto, composição farmacêutica, e, métodospara tratar uma doença em um animal em que aatividade de cisteìna protease contribui para apatologia e/ou sintomatologia da doença, e paratratar uma doença em um animal em que a atividadede catepsina s contribui para a patologia e/ousintomatologia da doença | |
| EA200100524A1 (ru) | Амиды антраниловой кислоты и их применение в качестве лекарственных средств | |
| ES2128846T3 (es) | Utilizacion del fumagilol y sus derivados para preparar los medicamentos destinados a combatir las infecciones intestinales. | |
| DE69629273D1 (de) | Zusammensetzungen enthaltend Propionyl-L-Carnitine und Hydroxyzitronensäure oder Pantothensäure | |
| MA26901A1 (fr) | Nouvelle composition pharmaceutique | |
| ES467828A1 (es) | Un procedimiento para preparar nuevos compuestos de cefem y cefam | |
| ES2178291T3 (es) | Uso de acidos 3-benzoil-aceticos, esteres, o amidas para el tratamiento del glaucoma glc1a. | |
| BR0114344A (pt) | Retinóides para o tratamento de enfisema | |
| EA199800721A1 (ru) | Ингибитор реваскуляризации | |
| ES2142030T3 (es) | Nuevos compuestos espiro-heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
| DK0451654T3 (da) | Anvendelse af N-alkylerede 1,4-dihydropyridin-dicarboxylsyreestere som lægemidler, nye forbindelser og fremgangsmåder til deres fremstilling | |
| ITRM930356A0 (it) | Uso di esteri sull'ossidrile della l-carnitina per produrre composizioni farmaceutiche per il trattamento di affezioni cutanee. | |
| ES2193722T3 (es) | Desformoterol y procedimiento para su preparacion. | |
| BR9807936A (pt) | Preparação farmacêutica imuno-tolerante de complexo de pró-trombina, processo para a produção de uma preparação, e, utilização de uma preparação | |
| AR012723A1 (es) | Derivados triptolidos utiles en el tratamiento de enfermedades autoinmunes y usos en la fabricacion de medicamentos | |
| PA8429701A1 (es) | Inhibicion de las metaloproteasas de matriz por acidos biariloxobutiricos sustituidos | |
| AR016382A1 (es) | Uso de un derivado del acido bencil-indazol metoxialcanoico. | |
| ITRM930365A0 (it) | Uso di esteri sull'ossidrile della l-carnitina con acidi aromatici perprodurre composizioni farmaceutiche per il trattamento di affezioni cutanee. | |
| CO4480025A1 (es) | Nuevos usos de ciertos derivados del indol en el tratamiento o profilaxis de trastornos medicos | |
| ES2187030T3 (es) | Una nueva sal. | |
| NO844889L (no) | Oksicam-derivater og fremgangsmaate til deres fremstilling | |
| IT8920358A0 (it) | Impiego di derivati della fosfatidil carnitina per la preparazione di composizioni farmaceutiche aventi attivita' nella terapia delle patologie dell'uomo associate con un danno neuronale. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |